SANA · Sana Biotechnology, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“Management has determined that the Company’s current capital resources may not be sufficient to fund its planned operations for at least one year from the date of this Quarterly Report, and there is substantial doubt as to the Company's ability to continue as a going concern.”View the 10-Q filed May 11, 2026
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 3, 4 and 5. Form 4 must be filed within two business days of the trade.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-07-06 | Bishop Hans Edgar |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Consists of fully vested restricted stock units. |
Common Stock
|
6,297 |
| 2026-06-04 | REICIN ALISE |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 4, 2027 and (ii) immediately prior to the 2027 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date. |
Stock Option (Right to Buy)
|
90,000 |
| 2026-06-04 | NELSEN ROBERT |
Director, 10% Owner |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 4, 2027 and (ii) immediately prior to the 2027 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date |
Stock Option (Right to Buy)
|
90,000 |
| 2026-06-04 | Mulligan Richard |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 4, 2027 and (ii) immediately prior to the 2027 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date. |
Stock Option (Right to Buy)
|
90,000 |
| 2026-06-04 | Bishop Hans Edgar |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 4, 2027 and (ii) immediately prior to the 2027 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date. |
Stock Option (Right to Buy)
|
90,000 |
| 2026-06-04 | Bilenker Joshua H. |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 4, 2027 and (ii) immediately prior to the 2027 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date. |
Stock Option (Right to Buy)
|
90,000 |
| 2026-06-04 | Yang Patrick Y |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 4, 2027 and (ii) immediately prior to the 2027 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date. |
Stock Option (Right to Buy)
|
90,000 |
| 2026-06-04 | Rosiello Robert L. |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 4, 2027 and (ii) immediately prior to the 2027 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date. |
Stock Option (Right to Buy)
|
90,000 |
| 2026-06-04 | Seitz Michelle |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 4, 2027 and (ii) immediately prior to the 2027 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date. |
Stock Option (Right to Buy)
|
90,000 |
| 2026-04-06 | Bishop Hans Edgar |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Consists of fully vested restricted stock units. |
Common Stock
|
7,763 |
| 2026-03-09 | Harr Steve |
Director, President & CEO |
Tax↓
|
Common Stock
|
11,526 |
| 2026-03-09 | Wyrick Susan D. |
See Remarks |
Tax↓
|
Common Stock
|
3,342 |
| 2026-03-09 | Wyrick Susan D. |
See Remarks |
Tax↓
|
Common Stock
|
1,045 |
| 2026-03-09 | Harr Steve |
Director, President & CEO |
Tax↓
|
Common Stock
|
12,819 |
| 2026-03-07 | Harr Steve |
Director, President & CEO |
Convert↑
|
Common Stock
|
50,000 |
| 2026-03-07 | Wyrick Susan D. |
See Remarks |
Convert↑
|
Common Stock
|
3,250 |
| 2026-03-07 | Wyrick Susan D. |
See Remarks |
Convert↓
Filing footnotes — Restricted Stock Units (Direct)
Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. ("Sana") common stock. The award vested as to 25% of the restricted stock units on each of March 7, 2025 and 2026, and the remaining restricted stock units will vest in two equal installments on each of March 7, 2027 and 2028, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date. |
Restricted Stock Units
|
3,250 |
| 2026-03-07 | Harr Steve |
Director, President & CEO |
Convert↓
Filing footnotes — Restricted Stock Units (Direct)
Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. ("Sana") common stock. The award vested as to 25% of the restricted stock units on each of March 7, 2025 and 2026, and the remaining restricted stock units will vest in two equal installments on each of March 7, 2027 and 2028, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date. |
Restricted Stock Units
|
50,000 |
| 2026-03-06 | Wyrick Susan D. |
See Remarks |
Convert↑
|
Common Stock
|
10,416 |
| 2026-03-06 | Wyrick Susan D. |
See Remarks |
Convert↓
Filing footnotes — Restricted Stock Units (Direct)
Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. ("Sana") common stock. The award vested as to 25% of the restricted stock units on March 6, 2026, and the remaining restricted stock units will vest in three equal installments on each of March 6, 2027, 2028 and 2029, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date. |
Restricted Stock Units
|
10,416 |
| 2026-03-06 | Harr Steve |
Director, President & CEO |
Convert↑
|
Common Stock
|
41,666 |
| 2026-03-06 | Harr Steve |
Director, President & CEO |
Convert↓
Filing footnotes — Restricted Stock Units (Direct)
Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. ("Sana") common stock. The award vested as to 25% of the restricted stock units on March 6, 2026, and the remaining restricted stock units will vest in three equal installments on each of March 6, 2027, 2028 and 2029, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date. |
Restricted Stock Units
|
41,666 |
| 2026-03-05 | Harr Steve |
Director, President & CEO |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The option vests and becomes exercisable as to 25% of the underlying shares on March 5, 2027 and in 36 equal monthly installments thereafter, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date. |
Stock Option (Right to Buy)
|
900,000 |
| 2026-03-05 | Wyrick Susan D. |
See Remarks |
Award↑
Filing footnotes — Restricted Stock Units (Direct)
Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. ("Sana") common stock. The restricted stock units vest in four equal installments on each of March 5, 2027, 2028, 2029 and 2030, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date. |
Restricted Stock Units
|
45,833 |
| 2026-03-05 | Harr Steve |
Director, President & CEO |
Award↑
Filing footnotes — Restricted Stock Units (Direct)
Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. ("Sana") common stock. The restricted stock units vest in four equal installments on each of March 5, 2027, 2028, 2029 and 2030, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date. |
Restricted Stock Units
|
200,000 |
| 2026-03-05 | Wyrick Susan D. |
See Remarks |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The option vests and becomes exercisable as to 25% of the underlying shares on March 5, 2027 and in 36 equal monthly installments thereafter, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date. |
Stock Option (Right to Buy)
|
206,250 |
| 2026-03-03 | Wyrick Susan D. |
See Remarks |
Tax↓
|
Common Stock
|
491 |
| 2026-03-02 | Wyrick Susan D. |
See Remarks |
Convert↑
|
Common Stock
|
1,525 |
| 2026-03-02 | Wyrick Susan D. |
See Remarks |
Convert↓
Filing footnotes — Restricted Stock Units (Direct)
Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. ("Sana") common stock. The award vested as to 25% of the restricted stock units on each of March 2, 2024, 2025 and 2026, and the remaining restricted stock units will vest on March 2, 2027, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through such date. |
Restricted Stock Units
|
1,525 |
| 2026-02-17 | Piper Brian |
Chief Financial Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The option vests and becomes exercisable as to 25% of the underlying shares on February 17, 2027 and in 36 equal monthly installments thereafter, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date. |
Stock Option (Right to Buy)
|
900,000 |
| 2026-02-17 | Piper Brian |
Chief Financial Officer |
Other↑
|
No Securities Owned
|
0 |
| 2026-02-17 | Piper Brian |
Chief Financial Officer |
Award↑
Filing footnotes — Restricted Stock Units (Direct)
Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. ("Sana") common stock. The restricted stock units vest in four equal installments on each of February 17, 2027, 2028, 2029 and 2030, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date. |
Restricted Stock Units
|
200,000 |
| 2026-01-05 | Wyrick Susan D. |
See Remarks |
Tax↓
|
Common Stock
|
2,407 |
| 2026-01-05 | Bishop Hans Edgar |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Consists of fully vested restricted stock units. |
Common Stock
|
6,157 |
| 2026-01-02 | Wyrick Susan D. |
See Remarks |
Convert↓
Filing footnotes — Restricted Stock Units (Direct)
Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. common stock. The award vested as to 40% of the restricted stock units on January 2, 2025 and 60% of the restricted stock units on January 2, 2026. |
Restricted Stock Units
|
7,500 |
| 2026-01-02 | Wyrick Susan D. |
See Remarks |
Convert↑
|
Common Stock
|
7,500 |
| 2025-12-15 | Wyrick Susan D. |
See Remarks |
Tax↓
|
Common Stock
|
873 |
| 2025-12-13 | Wyrick Susan D. |
See Remarks |
Convert↓
Filing footnotes — Restricted Stock Units (Direct)
Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. common stock. The award vested as to 100% of the restricted stock units on December 13, 2025. |
Restricted Stock Units
|
3,400 |
| 2025-12-13 | Wyrick Susan D. |
See Remarks |
Convert↑
|
Common Stock
|
3,400 |
| 2025-12-04 | Wyrick Susan D. |
See Remarks |
Tax↓
|
Common Stock
|
2,565 |
| 2025-12-03 | Wyrick Susan D. |
See Remarks |
Convert↑
Filing footnotes — Common Stock (Direct)
Includes 3,000 shares acquired on November 14, 2025 pursuant to the ESPP. |
Common Stock
|
10,000 |
| 2025-12-03 | Wyrick Susan D. |
See Remarks |
Convert↓
Filing footnotes — Restricted Stock Units (Direct)
Each restricted stock unit represents a contingent right to receive one share of Sana common stock. The restricted stock units vested in two equal installments on each of June 3, 2025 and December 3, 2025. |
Restricted Stock Units
|
10,000 |
| 2025-10-06 | Bishop Hans Edgar |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Consists of fully vested restricted stock units. |
Common Stock
|
5,628 |
| 2025-07-07 | Bishop Hans Edgar |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Consists of fully vested restricted stock units. |
Common Stock
|
7,842 |
| 2025-06-05 | Rosiello Robert L. |
Director |
Other↑
|
No Securities Owned
|
0 |
| 2025-06-05 | Seitz Michelle |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 5, 2026 and (ii) immediately prior to the 2026 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date. |
Stock Option (Right to Buy)
|
80,000 |
| 2025-06-05 | Bishop Hans Edgar |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 5, 2026 and (ii) immediately prior to the 2026 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date. |
Stock Option (Right to Buy)
|
80,000 |
| 2025-06-05 | Mulligan Richard |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 5, 2026 and (ii) immediately prior to the 2026 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date. |
Stock Option (Right to Buy)
|
80,000 |
| 2025-06-05 | Wilderotter Mary Agnes |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 5, 2026 and (ii) immediately prior to the 2026 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date. |
Stock Option (Right to Buy)
|
80,000 |
| 2025-06-05 | Yang Patrick Y |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 5, 2026 and (ii) immediately prior to the 2026 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date. |
Stock Option (Right to Buy)
|
80,000 |